Skip to main content
HELPCybin Inc.Sell4.4·$13.75
HELP · Why this verdict

Why Cybin (HELP) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Cybin is a cash-burning, sub-floor-quality biotech that is technically overbought and carries heavy defensive options positioning, with the engine finding no clear directional edge despite momentum having cleared its bar -- a name flagged for exit on fundamentals even as short-term price action runs hot.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The company is burning cash with negative free cash flow, has no competitive moat, and posted a weak Piotroski score, pulling quality below the engine's minimum floor and triggering an exit signal.

Stable
Quality breakdown
Expectation
Quality remains below the floor and cash burn continues over the next 12 months.

CounterVolume has been accumulating rather than distributing even as the fundamentals stay weak, which is unusual for a name in genuine distress.

The stock is technically overbought with an RSI near 76 while trading above its 200-day moving average and showing rising on-balance volume, a combination pointing to an extended rally.

Improving
Momentum breakdown
Expectation
Momentum stays elevated above the 200-day average over the next 12 months.

CounterAnalyst coverage is light enough to dampen the signal, so the move could be an unreliable, thinly traded speculative run rather than durable strength.

Options positioning skews notably defensive, with a put/call ratio near 4.5-to-1 and implied volatility around 96%.

Improving
Risk breakdown
Expectation
The put/call ratio and implied volatility remain elevated over the next 12 months.

CounterRecent analyst attention flagged in the news could shift sentiment and reduce hedging demand quickly.

Despite momentum clearing its threshold, the engine finds no clear directional edge in the setup, consistent with a name lacking a well-defined trading rationale.

Stable
Edge rationale
Expectation
The no-edge classification persists over the next 12 months.

CounterThe most recent quarter's earnings surprise turned positive after three straight misses, a change in trend that could eventually translate into a clearer directional edge.

Per-dimension breakdown

Value

5.0/10data confidence 50%

Quality

1.2/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin0.0
Op margin0.0
Net margin0.0
Current ratio5.0
FCF quality0.0
Moat3.8
Piotroski F2.2
  • Cash-burning (FCF negative)
  • No competitive moat
  • Weak Piotroski F-Score: 2/9
  • Quality concerns

Growth

5.0/10data confidence 50%

Momentum

5.8/10data confidence 100%
ComponentSub-score
RSI5.0
MACD1.1
OBV10.0
MA position9.0
Volume3.8
  • Volume accumulation (rising OBV)
  • Above 200-day MA

Sentiment

6.6/10data confidence 100%
ComponentSub-score
Analyst rating5.0
Price target10.0
erm sentiment5.0
  • Analyst upside: 205%

Insider

5.0/10data confidence 50%

Peer rank

3.9/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank0.5
growth rank5.0

Technical

3.9/10data confidence 100%
ComponentSub-score
bollinger0.7
support resistance1.8
52w position9.1

Risk (lower is worse)

5.7/10data confidence 100%
ComponentSub-score
days to cover9.4
volatility0.0
put call10.0
implied vol0.0
beta9.2
  • High IV: 90%

Catalyst

2.5/10data confidence 100%
ComponentSub-score
erm5.0
earnings history0.0
earnings timing5.0
surprise avg0.0
  • Earnings concerns: 1B/3M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (7)
  • MOMENTUM:5.8>=5.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:63d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)

none

Warning (1)
  • ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID

Setup No clear chart pattern; technical signals are mixed

EdgeNo clear edge No clear edge identified

SuitabilitySpeculative Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects clean gate clearance against Sentiment at 6.6 and asymmetric R:R of 0.00.

The strongest dimensions are Sentiment at 6.6, Momentum at 5.8, and Risk (lower is worse) at 5.7; the weakest are Quality at 1.2, Catalyst at 2.5, and Technical at 3.9. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Cash Burn Quality Below Floor

    Trip ifThe quality score rises above 4.0 (the engine's floor), up from about 1.2 currently.

  • P2Overbought Momentum With Accumulation

    Trip ifRSI falls below 60 (a neutral read), down from around 76 currently.

  • P3Elevated Options Skew

    Trip ifPut/call ratio falls below 2.0, down from about 4.5 currently.

  • P4No Clear Directional Edge

    Trip ifThe asymmetry ratio rises above 1.5, moving the setup out of a no-edge classification, up from near 0 currently.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks HELP Why this verdict